Biodexa Pharmaceuticals (BDRX) Preferred Dividend Payments (2014 - 2024)
Biodexa Pharmaceuticals (BDRX) reported Preferred Dividend Payments of -$1.0 million for Q4 2024, down 16632.09% on a YoY basis from N/an in Q1 2024, and down 16632.09% sequentially from -$6205.8 in Q4 2023.
Biodexa Pharmaceuticals (BDRX) Preferred Dividend Payments (2014 - 2024) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 6 years of Preferred Dividend Payments data on file, last reported at -$1.0 million in Q4 2024.
- For the quarter ending Q4 2024, Preferred Dividend Payments fell 16632.09% year-over-year to -$1.0 million; the trailing twelve-month figure through Dec 2024 stood at -$1.1 million (down 834.01% YoY), and the FY2024 full-year result was -$1.0 million, down 16596.15% from the prior year.
- Preferred Dividend Payments fell to -$1.0 million in Q4 2024, from -$6205.8 in the prior quarter.
- In the past five years, Preferred Dividend Payments ranged from a high of -$2696.0 in Q4 2021 to a low of -$1.0 million in Q4 2024.
- A 5-year average of -$230196.1 and a median of -$6205.8 in 2023 frame the typical range for Preferred Dividend Payments.
- Across the five-year window, Preferred Dividend Payments surged 97.28% in 2021 and sank 16632.09% in 2024, its largest moves.
- Tracing BDRX's Preferred Dividend Payments over 5 years: stood at -$99033.8 in 2020, then surged by 97.28% to -$2696.0 in 2021, then sank by 74.02% to -$4691.7 in 2022, then tumbled by 32.27% to -$6205.8 in 2023, then slumped by 16632.09% to -$1.0 million in 2024.
- Business Quant data shows BDRX's Preferred Dividend Payments at -$1.0 million in Q4 2024, -$6205.8 in Q4 2023, and -$4691.7 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.04 Mn |
| Dec 31, 2023 | -6,205.76 |
| Dec 31, 2022 | -4,691.71 |
| Dec 31, 2021 | -2,696.02 |
| Dec 31, 2020 | -99,033.83 |
| Dec 31, 2014 | -69,713.74 |